Shingles is not a minor skin problem; it is a viral reactivation that can permanently rewire the nervous system. When varicella zoster virus escapes immune surveillance in dorsal root ganglia, it inflames sensory nerves and the skin they supply, setting up damage that does not always heal.
This damage often evolves into postherpetic neuralgia, a chronic neuropathic pain syndrome in which injured axons fire erratically and spinal cord circuits remain sensitized. Patients can experience burning or electric shock sensations from the lightest touch, driven by persistent peripheral and central sensitization rather than any ongoing rash on the surface.
Beyond pain, shingles increases the risk of ischemic stroke and transient ischemic attack, as viral inflammation affects cerebral arteries and promotes endothelial dysfunction and thrombosis. For some, that means a single dermatome flare becomes a vascular event that reshapes mobility, cognition and long‑term disability trajectories, with costs that cascade across families and health systems.
An effective recombinant zoster vaccine exists, designed to boost cell‑mediated immunity and reduce viral reactivation. Yet adult immunization rates remain low, a classic failure of risk perception and marginal utility: people underestimate an invisible hazard and delay a preventive step that could sharply reduce pain, stroke risk and avoidable neurological injury.
